Shilpa Saralaya
Internal Medicine · Amarillo, TXNPI 1265506836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,478 and has fallen 68.8% since, to $461 in 2022. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$626
- Amgen$600
- AstraZeneca$559
- Kowa Pharmaceuticals America, Inc.$385
- Pfizer$347
- Takeda Pharmaceuticals U.S.A., Inc.$337
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $626 |
| Amgen(2 entities) | 32 | $600 |
| AstraZeneca | 35 | $559 |
| Kowa Pharmaceuticals America, Inc. | 26 | $385 |
| Pfizer | 18 | $347 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $337 |
| E.r. Squibb & Sons, L.L.C. | 18 | $285 |
| Lilly USA, LLC | 11 | $190 |
| Amarin Pharma, Inc. | 9 | $163 |
| AbbVie(2 entities) | 10 | $155 |
| Novartis | 9 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $126 |
| Regeneron Healthcare Solutions, Inc. | 6 | $99 |
| GSK | 4 | $80 |
| Bayer | 4 | $73 |
| Merck | 5 | $71 |
| Eisai Inc. | 4 | $62 |
| Johnson & Johnson | 3 | $62 |
| Daiichi Sankyo Inc. | 4 | $55 |
| Boehringer Ingelheim | 3 | $55 |
| Medicure Pharma Inc. | 2 | $54 |
| Astellas Pharma US Inc | 2 | $40 |
| Vivus LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Biogen | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
| Vistapharm, Inc. | 1 | $12 |
How this compares
$4,733 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Amarillo
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.